{"id":32269,"date":"2017-04-12T12:00:00","date_gmt":"2017-04-12T12:00:00","guid":{"rendered":"https:\/\/www.euforea.org\/news\/nieuwe-ontwikkelingen-in-biologicals-voor-crswnp\/"},"modified":"2017-04-12T12:00:00","modified_gmt":"2017-04-12T12:00:00","slug":"nieuwe-ontwikkelingen-in-biologicals-voor-crswnp","status":"publish","type":"news","link":"https:\/\/www.euforea.org\/nl\/news\/nieuwe-ontwikkelingen-in-biologicals-voor-crswnp\/","title":{"rendered":"Nieuwe ontwikkelingen in biologicals voor CRSwNP"},"content":{"rendered":"<div class=\"paragraph paragraph--text-columns paragraph-id--1391 paragraph--type--text-columns paragraph--view-mode--default clearfix paragraph--text-columns--1col\">\n<div class=\"inner--wide\">\n<div class=\"text__text text text--paragraph\">\n<h2>Rhinology Future Debates 2016<\/h2>\n<p>Prof. Claire Hopkins (VK) modereert deze sessie over de nieuwe monoklonale antilichamen voor chronische rhinosinusitis met neuspoliepen (CRSwNP). De besproken punten in dit debat hebben betrekking op de onvervulde behoeften, de uitdaging van nieuwe behandelingen, vragen ter overweging voor het panel en Dupilumab bij type 2-inflammatie. <\/p>\n<h3>Panelleden<\/h3>\n<p>Prof. Claus Bachert, prof. Manuel Bernal, prof. Wytske Fokkens en prof. Peter Hellings.<\/p>\n<\/div><\/div>\n<\/p><\/div>\n<p>,  <\/p>\n<div class=\"paragraph paragraph--text-columns paragraph-id--1392 paragraph--type--text-columns paragraph--view-mode--default clearfix paragraph--text-columns--1col\">\n<div class=\"inner--wide\">\n<div class=\"text__text text text--paragraph\">\n<div class=\"video-container\">\n<center><iframe width=\"560\" height=\"315\" src=\"https:\/\/www.youtube.com\/embed\/D9PBHqQU9GM?rel=0\" title=\"YouTube-videospeler\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture\" allowfullscreen=\"\"><\/iframe><\/center>\n<\/div>\n<\/div><\/div>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Rhinology Future Debates 2016 Prof. Claire Hopkins (VK) modereert deze sessie over de nieuwe monoklonale antilichamen voor chronische rhinosinusitis met neuspoliepen (CRSwNP). De besproken punten in dit debat hebben betrekking op de onvervulde behoeften, de uitdaging van nieuwe behandelingen, vragen ter overweging voor het panel en Dupilumab bij type 2-inflammatie. Panelleden Prof. Claus Bachert, prof. Manuel Bernal, prof. Wytske Fokkens en prof. Peter Hellings. ,<\/p>\n","protected":false},"author":1,"featured_media":32289,"comment_status":"open","ping_status":"closed","template":"","meta":{"footnotes":""},"categories":[233],"tags":[150,181,234,235,236],"class_list":["post-32269","news","type-news","status-publish","has-post-thumbnail","hentry","category-rhinology-future-debates","tag-chronische-rhinosinusitis-crs","tag-biologicals","tag-rhinologie","tag-debatten","tag-rhinology-future-debates"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.3 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Nieuwe ontwikkelingen in biologicals voor CRSwNP - EUFOREA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.euforea.org\/nl\/news\/nieuwe-ontwikkelingen-in-biologicals-voor-crswnp\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nieuwe ontwikkelingen in biologicals voor CRSwNP\" \/>\n<meta property=\"og:description\" content=\"Rhinology Future Debates 2016 Prof. Claire Hopkins (VK) modereert deze sessie over de nieuwe monoklonale antilichamen voor chronische rhinosinusitis met neuspoliepen (CRSwNP). De besproken punten in dit debat hebben betrekking op de onvervulde behoeften, de uitdaging van nieuwe behandelingen, vragen ter overweging voor het panel en Dupilumab bij type 2-inflammatie. Panelleden Prof. Claus Bachert, prof. Manuel Bernal, prof. Wytske Fokkens en prof. Peter Hellings. ,\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.euforea.org\/nl\/news\/nieuwe-ontwikkelingen-in-biologicals-voor-crswnp\/\" \/>\n<meta property=\"og:site_name\" content=\"EUFOREA\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/euforea\/\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@euforea\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/nl\\\/news\\\/nieuwe-ontwikkelingen-in-biologicals-voor-crswnp\\\/\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/nl\\\/news\\\/nieuwe-ontwikkelingen-in-biologicals-voor-crswnp\\\/\",\"name\":\"Nieuwe ontwikkelingen in biologicals voor CRSwNP - EUFOREA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/nl\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/nl\\\/news\\\/nieuwe-ontwikkelingen-in-biologicals-voor-crswnp\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/nl\\\/news\\\/nieuwe-ontwikkelingen-in-biologicals-voor-crswnp\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/RFD20201620-20Biologicals20for20Chronic20Rhinosinusitis.jpeg\",\"datePublished\":\"2017-04-12T12:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/nl\\\/news\\\/nieuwe-ontwikkelingen-in-biologicals-voor-crswnp\\\/#breadcrumb\"},\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.euforea.org\\\/nl\\\/news\\\/nieuwe-ontwikkelingen-in-biologicals-voor-crswnp\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/nl\\\/news\\\/nieuwe-ontwikkelingen-in-biologicals-voor-crswnp\\\/#primaryimage\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/RFD20201620-20Biologicals20for20Chronic20Rhinosinusitis.jpeg\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/RFD20201620-20Biologicals20for20Chronic20Rhinosinusitis.jpeg\",\"width\":1280,\"height\":720},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/nl\\\/news\\\/nieuwe-ontwikkelingen-in-biologicals-voor-crswnp\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/nl\\\/kies-uw-traject\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/nl\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nieuwe ontwikkelingen in biologicals voor CRSwNP\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/nl\\\/#website\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/nl\\\/\",\"name\":\"EUFOREA\",\"description\":\"Inspiring the Future of Respiratory Care\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/nl\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.euforea.org\\\/nl\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/nl\\\/#organization\",\"name\":\"EUFOREA\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/nl\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/nl\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"width\":500,\"height\":500,\"caption\":\"EUFOREA\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/nl\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/euforea\\\/\",\"https:\\\/\\\/x.com\\\/euforea\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/euforea\",\"https:\\\/\\\/www.youtube.com\\\/c\\\/EUFOREA\",\"https:\\\/\\\/www.instagram.com\\\/euforeaofficial\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Nieuwe ontwikkelingen in biologicals voor CRSwNP - EUFOREA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.euforea.org\/nl\/news\/nieuwe-ontwikkelingen-in-biologicals-voor-crswnp\/","og_locale":"nl_NL","og_type":"article","og_title":"Nieuwe ontwikkelingen in biologicals voor CRSwNP","og_description":"Rhinology Future Debates 2016 Prof. Claire Hopkins (VK) modereert deze sessie over de nieuwe monoklonale antilichamen voor chronische rhinosinusitis met neuspoliepen (CRSwNP). De besproken punten in dit debat hebben betrekking op de onvervulde behoeften, de uitdaging van nieuwe behandelingen, vragen ter overweging voor het panel en Dupilumab bij type 2-inflammatie. Panelleden Prof. Claus Bachert, prof. Manuel Bernal, prof. Wytske Fokkens en prof. Peter Hellings. ,","og_url":"https:\/\/www.euforea.org\/nl\/news\/nieuwe-ontwikkelingen-in-biologicals-voor-crswnp\/","og_site_name":"EUFOREA","article_publisher":"https:\/\/www.facebook.com\/euforea\/","twitter_card":"summary_large_image","twitter_site":"@euforea","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.euforea.org\/nl\/news\/nieuwe-ontwikkelingen-in-biologicals-voor-crswnp\/","url":"https:\/\/www.euforea.org\/nl\/news\/nieuwe-ontwikkelingen-in-biologicals-voor-crswnp\/","name":"Nieuwe ontwikkelingen in biologicals voor CRSwNP - EUFOREA","isPartOf":{"@id":"https:\/\/www.euforea.org\/nl\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.euforea.org\/nl\/news\/nieuwe-ontwikkelingen-in-biologicals-voor-crswnp\/#primaryimage"},"image":{"@id":"https:\/\/www.euforea.org\/nl\/news\/nieuwe-ontwikkelingen-in-biologicals-voor-crswnp\/#primaryimage"},"thumbnailUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/RFD20201620-20Biologicals20for20Chronic20Rhinosinusitis.jpeg","datePublished":"2017-04-12T12:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.euforea.org\/nl\/news\/nieuwe-ontwikkelingen-in-biologicals-voor-crswnp\/#breadcrumb"},"inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.euforea.org\/nl\/news\/nieuwe-ontwikkelingen-in-biologicals-voor-crswnp\/"]}]},{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/www.euforea.org\/nl\/news\/nieuwe-ontwikkelingen-in-biologicals-voor-crswnp\/#primaryimage","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/RFD20201620-20Biologicals20for20Chronic20Rhinosinusitis.jpeg","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/RFD20201620-20Biologicals20for20Chronic20Rhinosinusitis.jpeg","width":1280,"height":720},{"@type":"BreadcrumbList","@id":"https:\/\/www.euforea.org\/nl\/news\/nieuwe-ontwikkelingen-in-biologicals-voor-crswnp\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.euforea.org\/nl\/kies-uw-traject\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/www.euforea.org\/nl\/news\/"},{"@type":"ListItem","position":3,"name":"Nieuwe ontwikkelingen in biologicals voor CRSwNP"}]},{"@type":"WebSite","@id":"https:\/\/www.euforea.org\/nl\/#website","url":"https:\/\/www.euforea.org\/nl\/","name":"EUFOREA","description":"Inspiring the Future of Respiratory Care","publisher":{"@id":"https:\/\/www.euforea.org\/nl\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.euforea.org\/nl\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"},{"@type":"Organization","@id":"https:\/\/www.euforea.org\/nl\/#organization","name":"EUFOREA","url":"https:\/\/www.euforea.org\/nl\/","logo":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/www.euforea.org\/nl\/#\/schema\/logo\/image\/","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","width":500,"height":500,"caption":"EUFOREA"},"image":{"@id":"https:\/\/www.euforea.org\/nl\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/euforea\/","https:\/\/x.com\/euforea","https:\/\/www.linkedin.com\/company\/euforea","https:\/\/www.youtube.com\/c\/EUFOREA","https:\/\/www.instagram.com\/euforeaofficial\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.euforea.org\/nl\/wp-json\/wp\/v2\/news\/32269","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.euforea.org\/nl\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.euforea.org\/nl\/wp-json\/wp\/v2\/types\/news"}],"author":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/nl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/nl\/wp-json\/wp\/v2\/comments?post=32269"}],"version-history":[{"count":0,"href":"https:\/\/www.euforea.org\/nl\/wp-json\/wp\/v2\/news\/32269\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/nl\/wp-json\/wp\/v2\/media\/32289"}],"wp:attachment":[{"href":"https:\/\/www.euforea.org\/nl\/wp-json\/wp\/v2\/media?parent=32269"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euforea.org\/nl\/wp-json\/wp\/v2\/categories?post=32269"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euforea.org\/nl\/wp-json\/wp\/v2\/tags?post=32269"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}